

# Mong-Hong Lee

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1761233/mong-hong-lee-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

83

papers

7,166

citations

36

h-index

84

g-index

90

ext. papers

7,714

ext. citations

9.3

avg, IF

5.37

L-index

#	Paper	IF	Citations
83	3,3'-Diindolylmethane Enhances Fluorouracil Sensitivity via Inhibition of Pyrimidine Metabolism in Colorectal Cancer. <i>Metabolites</i> , <b>2022</b> , 12, 410	5.6	0
82	Desmosomal COP9 regulates proteome degradation in arrhythmogenic right ventricular dysplasia/cardiomyopathy. <i>Journal of Clinical Investigation</i> , <b>2021</b> , 131,	15.9	3
81	Impact of diabetes on promoting the growth of breast cancer. <i>Cancer Communications</i> , <b>2021</b> , 41, 414-431,	11.4	2
80	Tumor-Associated Microbiota in Esophageal Squamous Cell Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , <b>2021</b> , 9, 641270	5.7	8
79	Harness the functions of gut microbiome in tumorigenesis for cancer treatment. <i>Cancer Communications</i> , <b>2021</b> , 41, 937-967	9.4	1
78	Diabetes mellitus type 2 drives metabolic reprogramming to promote pancreatic cancer growth. <i>Gastroenterology Report</i> , <b>2020</b> , 8, 261-276	3.3	5
77	CSN6-TRIM21 axis instigates cancer stemness during tumorigenesis. <i>British Journal of Cancer</i> , <b>2020</b> , 122, 1673-1685	8.7	3
76	ILF3 is a substrate of SPOP for regulating serine biosynthesis in colorectal cancer. <i>Cell Research</i> , <b>2020</b> , 30, 163-178	24.7	17
75	EGF Relays Signals to COP1 and Facilitates FOXO4 Degradation to Promote Tumorigenesis. <i>Advanced Science</i> , <b>2020</b> , 7, 2000681	13.6	8
74	Neoadjuvant metformin added to conventional chemotherapy synergizes anti-proliferative effects in ovarian cancer. <i>Journal of Ovarian Research</i> , <b>2020</b> , 13, 95	5.5	2
73	Factors associated with severity and mortality in patients with confirmed leptospirosis at a regional hospital in northern Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , <b>2020</b> , 53, 307-314	8.5	11
72	Discovery of Protein Degradation Machinery at the Desmosome Reveals Novel Triggers of the Desmosomal Disease, Arrhythmogenic Right Ventricular Cardiomyopathy. <i>FASEB Journal</i> , <b>2019</b> , 33, 829.6	9.9	1
71	C-type lectin receptors as potential targets for the treatment of gastrointestinal diseases related to fungal infection. <i>Gastroenterology Report</i> , <b>2019</b> , 7, 376-377	3.3	
70	Inhibitory Effects of the Extracts of Juglans sigillata Green Husks on the Proliferation, Migration and Survival of KYSE150 and EC9706 Human Esophageal Cancer Cell Lines. <i>Nutrition and Cancer</i> , <b>2019</b> , 71, 149-158	2.8	3
69	Dysbiosis of gut microbiota in promoting the development of colorectal cancer. <i>Gastroenterology Report</i> , <b>2018</b> , 6, 1-12	3.3	110
68	A hypoxia-responsive TRAF6-ATM-H2AX signalling axis promotes HIF1 $\alpha$ activation, tumorigenesis and metastasis. <i>Nature Cell Biology</i> , <b>2017</b> , 19, 38-51	23.4	60
67	Obesity-associated NLRC4 inflammasome activation drives breast cancer progression. <i>Nature Communications</i> , <b>2016</b> , 7, 13007	17.4	127

66	The cell cycle regulator 14-3-3 $\zeta$ opposes and reverses cancer metabolic reprogramming. <i>Nature Communications</i> , <b>2015</b> , 6, 7530	17.4	54
65	Circadian Clock Gene CRY2 Degradation Is Involved in Chemoresistance of Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2015</b> , 14, 1476-87	6.1	44
64	ERK2-Dependent Phosphorylation of CSN6 Is Critical in Colorectal Cancer Development. <i>Cancer Cell</i> , <b>2015</b> , 28, 183-97	24.3	47
63	Regulating the stability and localization of CDK inhibitor p27(Kip1) via CSN6-COP1 axis. <i>Cell Cycle</i> , <b>2015</b> , 14, 2265-73	4.7	22
62	CSN6 positively regulates c-Jun in a MEKK1-dependent manner. <i>Cell Cycle</i> , <b>2015</b> , 14, 3079-87	4.7	10
61	Kinetic Modeling and Constrained Reconstruction of Hyperpolarized [1-13C]-Pyruvate Offers Improved Metabolic Imaging of Tumors. <i>Cancer Research</i> , <b>2015</b> , 75, 4708-17	10.1	51
60	Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma. <i>Cancer Research</i> , <b>2015</b> , 75, 4131-42	10.1	26
59	Clinical characteristics, microbiology, and outcomes for patients with lung and disseminated nocardiosis in a tertiary hospital. <i>Journal of the Formosan Medical Association</i> , <b>2015</b> , 114, 742-9	3.2	18
58	COP9 signalosome subunit 6 (CSN6) regulates E6AP/UBE3A in cervical cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 28026-41	9.3	18
57	Maintenance Therapy Containing Metformin and/or Zylflamend for Advanced Prostate Cancer: A Case Series. <i>Case Reports in Oncological Medicine</i> , <b>2015</b> , 2015, 471861	0.9	6
56	CSN6 deregulation impairs genome integrity in a COP1-dependent pathway. <i>Oncotarget</i> , <b>2015</b> , 6, 11779-93	9.3	14
55	COP1 enhances ubiquitin-mediated degradation of p27Kip1 to promote cancer cell growth. <i>Oncotarget</i> , <b>2015</b> , 6, 19721-34	3.3	21
54	CSN6 drives carcinogenesis by positively regulating Myc stability. <i>Nature Communications</i> , <b>2014</b> , 5, 5384	17.4	48
53	Multi-gene fluorescence in situ hybridization to detect cell cycle gene copy number aberrations in young breast cancer patients. <i>Cell Cycle</i> , <b>2014</b> , 13, 1299-305	4.7	10
52	Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106,	9.7	78
51	High prevalence of cardiometabolic risk factors in Hispanic adolescents: correlations with adipocytokines and markers of inflammation. <i>Journal of Immigrant and Minority Health</i> , <b>2014</b> , 16, 865-73	2.2	9
50	Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies. <i>Cancer Biology and Medicine</i> , <b>2014</b> , 11, 1-19	5.2	234
49	Activation of Liver FGF21 in hepatocarcinogenesis and during hepatic stress. <i>BMC Gastroenterology</i> , <b>2013</b> , 13, 67	3	67

48	Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 71, 63-72	3.5	32
47	Deficiency of metabolic regulator FGFR4 delays breast cancer progression through systemic and microenvironmental metabolic alterations. <i>Cancer &amp; Metabolism</i> , <b>2013</b> , 1, 21	5.4	18
46	CDK inhibitor p57 (Kip2) is downregulated by Akt during HER2-mediated tumorigenicity. <i>Cell Cycle</i> , <b>2013</b> , 12, 935-43	4.7	34
45	DNA Damage-Mediated c-Myc Degradation Requires 14-3-3 Sigma <b>2013</b> , 1, 3-17		12
44	Ubiquitination-Mediated p57Kip2 Degradation by CSN5 Confers Cancer Cell Proliferation <b>2013</b> , 1, 133-144		6
43	Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells. <i>Cell Cycle</i> , <b>2012</b> , 11, 2314-26	4.7	33
42	Aurora B kinase phosphorylates and instigates degradation of p53. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, E1513-22	11.5	122
41	MiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN. <i>Cell Cycle</i> , <b>2012</b> , 11, 785-96	4.7	153
40	p53 negatively regulates Aurora A via both transcriptional and posttranslational regulation. <i>Cell Cycle</i> , <b>2012</b> , 11, 3433-42	4.7	45
39	HER2-Akt signaling in regulating COP9 signalosome subunit 6 and p53. <i>Cell Cycle</i> , <b>2012</b> , 11, 4181-90	4.7	31
38	FBXW7 is involved in Aurora B degradation. <i>Cell Cycle</i> , <b>2012</b> , 11, 4059-68	4.7	33
37	CDK inhibitor p57 (Kip2) is negatively regulated by COP9 signalosome subunit 6. <i>Cell Cycle</i> , <b>2012</b> , 11, 4633-41	4.7	35
36	Exenatide improves glucocorticoid-induced glucose intolerance in mice. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2011</b> , 4, 61-5	3.4	8
35	Roles of COP9 signalosome in cancer. <i>Cell Cycle</i> , <b>2011</b> , 10, 3057-66	4.7	98
34	The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. <i>Journal of Cellular and Molecular Medicine</i> , <b>2011</b> , 15, 825-36	5.6	62
33	14-3-3sigma exerts tumor-suppressor activity mediated by regulation of COP1 stability. <i>Cancer Research</i> , <b>2011</b> , 71, 884-94	10.1	51
32	Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers. <i>Journal of Clinical Investigation</i> , <b>2011</b> , 121, 851-65	15.9	76
31	Nuclear export regulation of COP1 by 14-3-3 in response to DNA damage. <i>Molecular Cancer</i> , <b>2010</b> , 9, 243	42.1	36

30	Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. <i>Molecular Cancer</i> , <b>2010</b> , 9, 42	42.1	67
29	Interplay of 14-3-3 Family of Proteins with DNA Damage-Regulated Molecules in Checkpoint Control <b>2010</b> , 69-80		
28	E3 ubiquitin ligase COP1 regulates the stability and functions of MTA1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 17493-8	11.5	71
27	Intercepting Akt with DNzyme: A nasopharyngeal carcinoma story. <i>Cancer Biology and Therapy</i> , <b>2009</b> , 8, 372-4	4.6	
26	Farnesyltransferase inhibitors-induced autophagy: alternative mechanisms?. <i>Autophagy</i> , <b>2009</b> , 5, 129-31	10.2	16
25	Hypoxia-mediated up-regulation of Pim-1 contributes to solid tumor formation. <i>American Journal of Pathology</i> , <b>2009</b> , 175, 400-11	5.8	69
24	Roles of Negative and Positive Growth Regulators in Nasopharyngeal Carcinoma <b>2009</b> , 273-294		
23	Autophagy induced by farnesyltransferase inhibitors in cancer cells. <i>Cancer Biology and Therapy</i> , <b>2008</b> , 7, 1679-84	4.6	31
22	Aurora-B kinase inhibitors for cancer chemotherapy. <i>Mini-Reviews in Medicinal Chemistry</i> , <b>2008</b> , 8, 1514-25	3.2	15
21	Roles for CSN5 in control of p53/MDM2 activities. <i>Journal of Cellular Biochemistry</i> , <b>2008</b> , 103, 1219-30	4.7	62
20	Regulation of the p53-MDM2 pathway by 14-3-3 sigma and other proteins. <i>Seminars in Cancer Biology</i> , <b>2006</b> , 16, 225-34	12.7	86
19	Modified p27 Kip1 is efficient in suppressing HER2-mediated tumorigenicity. <i>Journal of Cellular Biochemistry</i> , <b>2006</b> , 98, 128-38	4.7	9
18	Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway. <i>Cell Cycle</i> , <b>2006</b> , 5, 1654-61	4.7	23
17	Interferon-inducible protein IFI $\alpha$ 1 functions as a negative regulator of HDM2. <i>Molecular and Cellular Biology</i> , <b>2006</b> , 26, 1979-96	4.8	34
16	14-3-3sigma, a p53 regulator, suppresses tumor growth of nasopharyngeal carcinoma. <i>Molecular Cancer Therapeutics</i> , <b>2006</b> , 5, 253-60	6.1	43
15	DNA damage-induced protein 14-3-3 sigma inhibits protein kinase B/Akt activation and suppresses Akt-activated cancer. <i>Cancer Research</i> , <b>2006</b> , 66, 3096-105	10.1	75
14	Functional Regulation of CIP/KIP CDK Inhibitors. <i>Enzyme Inhibitors Series</i> , <b>2006</b> , 29-53		
13	Constitutively active FOXO4 inhibits Akt activity, regulates p27 Kip1 stability, and suppresses HER2-mediated tumorigenicity. <i>Oncogene</i> , <b>2005</b> , 24, 1924-35	9.2	65

12	Tumor suppressor ARF inhibits HER-2/neu-mediated oncogenic growth. <i>Oncogene</i> , <b>2004</b> , 23, 7132-43	9.2	16
11	Regulators of G1 cyclin-dependent kinases and cancers. <i>Cancer and Metastasis Reviews</i> , <b>2003</b> , 22, 435-49	9.6	91
10	Molecular targets for cell cycle inhibition and cancer therapy. <i>Expert Opinion on Therapeutic Patents</i> , <b>2003</b> , 13, 329-346	6.8	5
9	14-3-3 sigma positively regulates p53 and suppresses tumor growth. <i>Molecular and Cellular Biology</i> , <b>2003</b> , 23, 7096-107	4.8	193
8	Correlation of p27 protein expression with HER-2/neu expression in breast cancer. <i>Molecular Carcinogenesis</i> , <b>2001</b> , 30, 169-75	5	41
7	A case-control study of unilateral and bilateral breast carcinoma patients. <i>Cancer</i> , <b>2001</b> , 91, 1845-53	6.4	60
6	p27 Kip1 inhibits HER2/neu-mediated cell growth and tumorigenesis. <i>Oncogene</i> , <b>2001</b> , 20, 3695-702	9.2	45
5	Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. <i>Nature Cell Biology</i> , <b>2001</b> , 3, 245-52	23.4	902
4	Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 24735-9	5.4	99
3	Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 23106-12	5.4	232
2	Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. <i>Nature</i> , <b>1994</b> , 372, 570-3	50.4	857
1	Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. <i>Cell</i> , <b>1994</b> , 78, 59-66	56.2	1928